[
  {
    "question": "Old patient came with low grade fever, meningism, encephalopathy and acute flaccid paralysis, lymphadenopathy What is your diagnosis?",
    "option_a": "(WNV) is correct because the cluster of symptoms\u2014low",
    "option_b": "(Polio) is unlikely given the patient\u2019s age, the rarity of polio due to vaccination programs, and the uncommon presence of lymphadenopathy. Option c (HIV) typically produces a more subacute or chronic picture rather than an acute viral meningitis with AFP. Other options do not align with the multi",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-infectious",
    "explanation": "West Nile Virus (WNV) is an arthropod\u2010borne flavivirus transmitted by mosquitoes. In its neuroinvasive form, it can present with a combination of meningitis, encephalitis, and acute flaccid paralysis (AFP), especially in elderly patients. The presence of systemic findings \u2013 including low-grade fever and even lymphadenopathy \u2013 points toward a viral illness with multiorgan involvement. After a mosquito bite, WNV replicates in regional lymph nodes. In some patients, particularly the elderly or immunocompromised, the virus crosses the blood\u2013brain barrier resulting in inflammation of the meninges (meningism), brain parenchyma (encephalitis), and anterior horn cells leading to AFP. The local immune response and cytokine release contribute to neuronal injury and systemic lymphadenopathy. Clinically, patients often present with fever, headache, neck stiffness, altered mental status, and focal neurological deficits. The acute flaccid paralysis results from involvement of the motor neurons and may mimic polio. The elderly are particularly vulnerable to the neuroinvasive form, and the systemic lymphadenopathy may help differentiate it from other causes of AFP in younger individuals. Diagnosis is based on clinical suspicion in the setting of a compatible history and supported by laboratory tests. CSF analysis typically shows lymphocytic pleocytosis and may have positive WNV IgM antibodies. Neuroimaging (MRI/CT) is used to exclude other diagnoses. Differential diagnoses include poliomyelitis (rare due to vaccination), other viral encephalitides, and atypical presentations of HIV infection. Management of neuroinvasive WNV is mainly supportive. This includes intensive care support as needed, management of raised intracranial pressure, and rehabilitation. There is no proven antiviral therapy. In pregnant or lactating women, supportive care remains the cornerstone; no contraindicated medications are typically used, but close monitoring is essential. Preventive measures (mosquito control and personal protective measures) are critical in at-risk populations. Option a (WNV) is correct because the cluster of symptoms\u2014low-grade fever, meningism, encephalopathy, AFP, and lymphadenopathy especially in an elderly patient\u2014is classic for neuroinvasive WNV. Option b (Polio) is unlikely given the patient\u2019s age, the rarity of polio due to vaccination programs, and the uncommon presence of lymphadenopathy. Option c (HIV) typically produces a more subacute or chronic picture rather than an acute viral meningitis with AFP. Other options do not align with the multi-system involvement seen in this case. 1. Neuroinvasive WNV often presents in the elderly with a combination of meningitis, encephalitis, and AFP. 2. There is no specific antiviral treatment, and care is supportive. 3. The presence of systemic features such as lymphadenopathy can help differentiate WNV from other causes of AFP. Recent studies and guidelines reinforce that supportive care is the mainstay treatment for WNV neuroinvasive disease. Ongoing research into immunomodulatory approaches has not yet provided an alternative to supportive management. Updated CDC recommendations continue to emphasize mosquito bite prevention as the best strategy for avoiding infection.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient comatose, with retina findings typical for neuro-retinitis. Dx :",
    "option_a": "(Malaria) is incorrect because, although malaria can cause retinal changes, it does not produce neuroretinitis with the macular star sign. Option b (Syphilis) is correct since syphilis is a known cause of neuroretinitis and fits the clinical picture. Option c (Lyme disease) is less likely to present with this classic ocular finding, and Option d (HCV) is not typically associated with neuroretinitis.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuro-infectious",
    "explanation": "Neuroretinitis is characterized by optic disc edema accompanied by a macular star pattern of hard exudates. Although classically associated with cat-scratch disease (Bartonella henselae), in the absence of that option and given the systemic findings in a comatose patient, syphilis is a well\u2010recognized cause of neuroretinitis and other ocular inflammatory syndromes. Treponema pallidum invasion can cause inflammation of the optic nerve and adjacent retinal tissues. In neurosyphilis, the spirochete may induce a vasculitic process that leads to optic nerve involvement (papillitis) and subsequent exudation in the macula leading to the star formation. The inflammatory cascade can progress to involve the CNS, potentially leading to severe manifestations such as coma. The combination of a comatose state and characteristic retinal findings (optic disc swelling with a macular star) suggests central nervous system involvement by syphilis. Ocular syphilis can present in many ways, and neuroretinitis is one of its manifestations. In contrast, other infectious causes such as malaria or Lyme disease rarely produce these specific findings. Diagnosis requires a high index of suspicion. Serum tests such as RPR or VDRL along with confirmatory treponemal tests (e.g., FTA-ABS) are essential. CSF analysis should be performed in cases with neurological involvement to confirm neurosyphilis. Differential diagnoses include ocular manifestations from cat-scratch disease, Lyme disease, or inflammatory conditions, which can be differentiated by history, serologic studies, and ocular exam findings. The treatment for ocular and neurosyphilis is intravenous penicillin G for 10\u201314 days. In pregnant women, penicillin remains the treatment of choice as it is safe and prevents congenital syphilis. In lactating women, penicillin is also safe, with minimal excretion in breast milk. Alternative regimens may be considered in cases of penicillin allergy after desensitization. Option a (Malaria) is incorrect because, although malaria can cause retinal changes, it does not produce neuroretinitis with the macular star sign. Option b (Syphilis) is correct since syphilis is a known cause of neuroretinitis and fits the clinical picture. Option c (Lyme disease) is less likely to present with this classic ocular finding, and Option d (HCV) is not typically associated with neuroretinitis. 1. The macular star is a hallmark of neuroretinitis, seen in various infections including syphilis. 2. Ocular syphilis is a manifestation of neurosyphilis and necessitates CSF evaluation. 3. Penicillin remains the gold standard treatment, even during pregnancy and lactation. Recent guideline updates, including those from the CDC, underscore the need for prompt recognition and treatment of neurosyphilis with IV penicillin. There is an increased emphasis on ocular manifestations as early indicators of neurosyphilis, prompting early diagnostic workup to avert permanent visual impairment.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "In case of brain abscess, what is the poor prognostic factor",
    "option_a": "(Abscess near the ventricle) is correct as it is a well\u2010established poor prognostic factor due to the high risk of ventricular rupture and ensuing ventriculitis. Option b (Low GCS) is also recognized as a poor prognostic sign but in this MCQ the emphasis is on the anatomical risk presented by ventricular proximity. If presented with multiple answers, both would be valid; however, given the options provided, proximity to the ventricle is highlighted as the key factor.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-infectious",
    "explanation": "A brain abscess is a collection of pus within the brain parenchyma resulting from infection. Prognostic factors help clinicians gauge the risk of complications and mortality. Among them, abscess proximity to the ventricular system is critical because of the risk of rupture causing ventriculitis, a life\u2010threatening event. A low Glasgow Coma Scale (GCS) on presentation also correlates with poor outcomes. When an abscess is located adjacent to the ventricles, there is an increased risk of direct spread of infection into the ventricular system if the abscess ruptures. This can lead to ventriculitis, widespread inflammation, and septic complications. A low GCS indicates severe neurological compromise, likely due to mass effect, increased intracranial pressure, or diffuse infection. Patients with brain abscesses in proximity to the ventricles or those who present with significantly depressed levels of consciousness are at higher risk of rapid deterioration and poor outcomes. Clinically, this is reflected by higher rates of morbidity and mortality. Neuroimaging with contrast-enhanced CT or MRI is essential to evaluate the location and extent of an abscess. Differential diagnoses include neoplastic lesions, cystic tumors, infarcts, and demyelinating lesions. The periventricular location along with clinical findings helps in differentiating an abscess from these alternatives. Management involves a tiered approach: First-line treatment includes broad-spectrum IV antibiotics tailored to cover likely pathogens (gram-positive, gram-negative, and anaerobes) along with neurosurgical intervention (aspiration or excision) for larger abscesses. Special attention is required if the abscess is near the ventricle due to the elevated risk of rupture; such cases may necessitate more aggressive neurosurgical management. In pregnant or lactating women, antibiotic choices are carefully selected to avoid teratogenic effects while ensuring adequate CNS penetration; agents like penicillins and cephalosporins are generally favored. Option a (Abscess near the ventricle) is correct as it is a well\u2010established poor prognostic factor due to the high risk of ventricular rupture and ensuing ventriculitis. Option b (Low GCS) is also recognized as a poor prognostic sign but in this MCQ the emphasis is on the anatomical risk presented by ventricular proximity. If presented with multiple answers, both would be valid; however, given the options provided, proximity to the ventricle is highlighted as the key factor. 1. Abscesses abutting the ventricle are at high risk for rupture and rapidly deteriorating clinical course. 2. A low GCS on presentation is a red flag for severe intracranial infection. 3. Early imaging and aggressive intervention are crucial in these high-risk cases. Current studies and guidelines (including those from the IDSA) emphasize that abscesses in a periventricular location have a significantly higher mortality rate. There is ongoing research into optimal neurosurgical timing and antibiotic regimens, but the consensus remains that early and aggressive management improves outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Duration of acyclovir ttt in HSV encephalitis",
    "option_a": "(7 days) is insufficient as it does not fully suppress viral replication. Option b (14 days) is correct and represents the standard treatment duration. Option c (21 days) may be reserved for complicated cases but is not routinely used in all patients. Option d (72 hours) is grossly inadequate and would lead to treatment failure.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuro-infectious",
    "explanation": "Herpes Simplex Virus (HSV) encephalitis is a fulminant infection of the brain predominantly involving the temporal lobes. Acyclovir is the antiviral agent of choice. The duration of treatment is critical to ensure complete viral suppression and reduce relapse rates. HSV enters the central nervous system via retrograde neuronal transmission. Once in the brain, viral replication results in necrotizing inflammation predominantly affecting the temporal lobes. Inadequate treatment duration may fail to eradicate the virus completely, resulting in ongoing viral replication and potential relapse of the disease. Patients typically present with fever, altered mental status, seizures, and focal neurological deficits. Early initiation of acyclovir has been shown to improve outcomes, and a standard treatment course is essential for reducing morbidity and mortality. Diagnosis is based on clinical presentation supported by neuroimaging (MRI showing temporal lobe involvement) and CSF analysis, particularly PCR testing for HSV DNA which is highly sensitive and specific. Differential diagnoses include other causes of encephalitis such as varicella-zoster virus infection, autoimmune encephalitis, and bacterial meningoencephalitis. First-line management involves IV acyclovir administered for 14 days, which is the recommended duration in immunocompetent adults per IDSA guidelines. In immunocompromised patients or in cases with persistent CSF PCR positivity, an extended course (up to 21 days) may be warranted. For pregnant women, acyclovir is classified as pregnancy category B and is considered safe when used appropriately. Lactating mothers may also be treated with acyclovir, with benefits outweighing potential minimal risks. Option a (7 days) is insufficient as it does not fully suppress viral replication. Option b (14 days) is correct and represents the standard treatment duration. Option c (21 days) may be reserved for complicated cases but is not routinely used in all patients. Option d (72 hours) is grossly inadequate and would lead to treatment failure. 1. Early and adequate duration (14 days) of acyclovir treatment is crucial in HSV encephalitis. 2. Persistent neurological deficits may result from inadequate viral clearance. 3. Always consider extending therapy in immunocompromised patients. Recent evidence and updated IDSA guidelines emphasize a 14-day course of IV acyclovir as the standard treatment for HSV encephalitis. Studies have demonstrated that shorter courses are associated with higher relapse rates. Ongoing research is evaluating biomarkers such as serial CSF PCR levels to tailor the duration of therapy further.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient diagnosis with HIV one month back, he came now with paraparesis.",
    "option_a": "(HIV myelopathy) is correct as it best fits the clinical picture of progressive paraparesis in an HIV patient. Option b (HTLV",
    "option_b": "",
    "option_c": "(CMV myelitis) usually occurs in patients with advanced immunosuppression and presents acutely with systemic symptoms. Option d (Toxoplasmosis) more typically causes focal brain lesions with encephalopathy rather than an isolated myelopathy.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-infectious",
    "explanation": "HIV myelopathy (often referred to as vacuolar myelopathy) is a recognized complication in patients with HIV. It typically presents as a progressive, symmetric spastic paraparesis affecting the lower limbs, often with dorsal column involvement leading to impaired proprioception. The mechanism involves a slowly progressive degeneration of the spinal cord, particularly affecting the dorsal columns and lateral corticospinal tracts. Although the exact etiology is not completely understood, theories include direct HIV-related neurotoxicity and immune-mediated damage leading to demyelination and subsequent vacuolation within the spinal cord white matter. Clinically, patients may present with gradually worsening weakness in the legs, increased muscle tone (spasticity), and impaired balance or proprioception. Bladder dysfunction can also occur. The clinical picture of a patient recently diagnosed with HIV developing paraparesis fits well with HIV myelopathy, especially when other signs of opportunistic infections are absent. The workup typically involves MRI of the spinal cord, which may show nonspecific signal changes predominantly in the dorsal columns. Differential diagnoses include HTLV-1 myelopathy (which has a distinct epidemiological distribution), CMV myelitis (often seen in advanced AIDS with systemic symptoms), and other inflammatory or compressive myelopathies. Cerebrospinal fluid (CSF) analysis and clinical correlation help refine the diagnosis. The primary management is optimizing antiretroviral therapy (ART) to control HIV replication, as improvements in immune function may help slow progression. Symptomatic treatment for spasticity (e.g., baclofen, tizanidine) and supportive therapies (physical therapy, occupational therapy) are integral. In pregnancy and lactation, ART regimens are selected based on safety profiles (many are category B or C with extensive clinical experience) with close monitoring to balance maternal health and fetal safety. Option a (HIV myelopathy) is correct as it best fits the clinical picture of progressive paraparesis in an HIV patient. Option b (HTLV-1 myelopathy) is less likely due to epidemiologic differences and the absence of evidence of HTLV-1. Option c (CMV myelitis) usually occurs in patients with advanced immunosuppression and presents acutely with systemic symptoms. Option d (Toxoplasmosis) more typically causes focal brain lesions with encephalopathy rather than an isolated myelopathy. 1. Always consider HIV myelopathy in HIV patients with progressive lower limb spasticity. 2. MRI is a key diagnostic tool to evaluate the extent and pattern of spinal cord involvement. 3. Optimization of ART is crucial in managing neurologic complications of HIV. Recent studies emphasize that early and effective ART can stabilize or improve neurologic symptoms in HIV myelopathy. While no disease-specific therapy exists aside from supportive care, ongoing research is evaluating neuroprotective strategies in this patient population.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "HIV don\u2019t want you to till his wife",
    "option_a": "('Do not tell') is correct as it honors patient confidentiality and autonomy. Option b ('Tell her') is incorrect because it breaches the patient\u2019s confidentiality despite potential ethical conflicts; unilateral disclosure without consent is not justified unless specific legal criteria are met. Option c ('Contact health authority') is also incorrect, as this is typically reserved for public health reporting and not for partner notification without patient consent.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-infectious",
    "explanation": "Patient confidentiality is a foundational ethical and legal principle in medicine. In cases involving HIV, the patient\u2019s right to privacy must be respected as a precondition to building trust and ensuring long-term engagement in care. While there is no direct pathophysiology in this ethical scenario, the underlying principle is that breaching confidentiality can lead to stigma, discrimination, and a breakdown in the patient-provider relationship which may indirectly affect the patient\u2019s health outcomes. When an HIV-positive patient requests that his diagnosis not be disclosed to his spouse, the clinician must balance the duty of confidentiality with considerations of public health and partner safety. However, in most jurisdictions, unless there is a legal mandate or imminent risk, patient wishes predominate. This scenario does not require a diagnostic workup but rather a careful ethical and legal analysis. Differential ethical approaches in similar cases include unilateral disclosure (which breaches confidentiality) and mandatory reporting (reserved for specific legally defined scenarios). The first-line approach is to respect patient autonomy and confidentiality (Option a \u2013 'Do not tell') while gently counseling the patient about the benefits of informing his spouse for her health. Secondarily, the clinician can advise on safe practices and suggest voluntary disclosure. In pregnancy or lactation situations, similar ethical considerations apply as maintaining a confidential therapeutic relationship is essential regardless of the patient's reproductive status. Legal requirements for partner notification vary by jurisdiction, and one must be familiar with local laws, but generally, forced disclosure is avoided unless mandated. Option a ('Do not tell') is correct as it honors patient confidentiality and autonomy. Option b ('Tell her') is incorrect because it breaches the patient\u2019s confidentiality despite potential ethical conflicts; unilateral disclosure without consent is not justified unless specific legal criteria are met. Option c ('Contact health authority') is also incorrect, as this is typically reserved for public health reporting and not for partner notification without patient consent. 1. Respecting patient confidentiality is critical in HIV management to reduce stigma and promote engagement with care. 2. Counseling patients about the importance of partner notification should be done empathetically without breaching confidentiality. 3. Always be aware of local legal mandates regarding partner notification in HIV. Current guidelines from organizations such as the CDC and WHO emphasize patient confidentiality in HIV care. Recent ethics literature reinforces that forced disclosure often undermines the patient-provider relationship and may deter patients from seeking care.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Prevention of post herpetic neuralgia",
    "option_a": "(Steroids) is incorrect as their role is limited to reducing acute pain and inflammation but they have not been proven to prevent PHN. Option b (Carbamazepine) is used primarily in trigeminal neuralgia and has no evidence supporting its use in preventing PHN. Option c (Antiviral) is correct because multiple studies support that early administration reduces VZV replication and nerve damage, thereby decreasing the incidence and severity of PHN. Option d (Pregabalin) is effective for treating established PHN by reducing neuropathic pain but does not prevent its development when given during the acute phase of herpes zoster.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuro-infectious",
    "explanation": "Herpes zoster (shingles) arises from reactivation of latent varicella-zoster virus (VZV). Early intervention with antiviral therapy is the key strategy not only to limit the acute viral process but also to reduce the risk of developing postherpetic neuralgia (PHN), a chronic neuropathic pain condition. The reactivation of VZV leads to inflammation and damage of the sensory nerves. Early antiviral therapy reduces viral replication, decreases neuronal injury and inflammation, and therefore minimizes nerve damage that would otherwise result in the persistent pain characteristic of PHN. In patients presenting with herpes zoster, initiating antiviral treatment within 72 hours of rash onset has been shown to reduce the duration and severity of acute symptoms as well as the likelihood of developing PHN. In contrast, agents like steroids may reduce acute inflammation but do not prevent the chronic nerve damage leading to PHN. The diagnosis is primarily clinical based on the characteristic unilateral vesicular rash in a dermatomal distribution. Differential diagnoses include other dermatomal rashes or neuropathic pain syndromes. Early antiviral therapy is indicated once herpes zoster is recognized. First-line management for herpes zoster to prevent PHN is the initiation of antiviral agents such as acyclovir, valacyclovir, or famciclovir within 72 hours of rash onset. Adjunctive pain management may include analgesics and, in some cases, short courses of corticosteroids for acute pain relief (though not for PHN prevention). In pregnancy and lactation, acyclovir is generally considered safe (pregnancy category B), and its early use is recommended when indicated due to its established safety record and ability to reduce complications. Option a (Steroids) is incorrect as their role is limited to reducing acute pain and inflammation but they have not been proven to prevent PHN. Option b (Carbamazepine) is used primarily in trigeminal neuralgia and has no evidence supporting its use in preventing PHN. Option c (Antiviral) is correct because multiple studies support that early administration reduces VZV replication and nerve damage, thereby decreasing the incidence and severity of PHN. Option d (Pregabalin) is effective for treating established PHN by reducing neuropathic pain but does not prevent its development when given during the acute phase of herpes zoster. 1. Initiate antiviral therapy within 72 hours of rash onset in patients with herpes zoster to reduce the risk of PHN. 2. Recognize that while steroids may help with acute symptoms, they have not proven benefits in preventing PHN. 3. In pregnant or lactating patients, acyclovir is preferred given its safety profile. Recent randomized controlled trials and systematic reviews reinforce the benefit of early antiviral therapy in reducing PHN. Current guidelines consistently advocate for the use of antivirals as the primary preventive measure, with emphasis on the timing of therapy to optimize outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Poor prognostic factors of brain abscesses",
    "option_a": "Multiple at the time of initiation of treatment",
    "option_b": "Deep located abscess near CSF space",
    "option_c": "Decrease LOC at the time on treatment initiation",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuro-infectious",
    "explanation": "Brain abscesses are focal infections within the brain parenchyma. Certain factors are associated with a worse prognosis. Recognizing poor prognostic indicators is critical for risk stratification and management. The severity of a brain abscess can be influenced by factors such as multiple lesions (suggesting widespread infection), deep-seated abscesses near the cerebrospinal fluid (CSF) spaces (which increase the risk of rupture into the ventricular system), and a decreased level of consciousness at the time of treatment (reflecting advanced neurological compromise). Rupture into the ventricles can lead to meningitis and a dramatic clinical decline. Patients presenting with multiple abscesses, lesions adjacent to CSF spaces, or reduced consciousness are likely to have more aggressive disease, higher rates of complications, and worse overall outcomes. Early identification of these features is crucial for timely and aggressive management. Diagnosis is based on neuroimaging (CT or MRI) which helps in assessing the number, size, and location of abscesses. Differentiation from other focal CNS lesions (e.g., tumors, demyelinating lesions) is essential. Clinical examination and laboratory evaluation (including blood cultures and sometimes stereotactic biopsy) further contribute to the diagnosis. Management involves a combination of high-dose, broad-spectrum intravenous antibiotics and often surgical intervention (aspiration or excision) depending on the size, number, and location of the abscesses. In the presence of poor prognostic factors, more aggressive management (e.g., early neurosurgical drainage) is warranted. In pregnant patients, antibiotic selection requires careful consideration of fetal safety (using agents that are known to be safe in pregnancy) and in the lactating mother, the excretion profiles of the drugs should be evaluated. Option a (Multiple abscesses) is a known poor prognostic factor because they suggest a more disseminated infection. Option b (Deep located abscess near CSF space) is also associated with a higher risk of intraventricular rupture and dissemination. Option c (Decreased level of consciousness at treatment initiation) reflects advanced disease and neurologic compromise. Therefore, Option d ('All of the above') is the correct answer as all these factors adversely impact prognosis. 1. Multiple brain abscesses and deep abscess locations are significant risk markers for worsened outcomes. 2. A decreased level of consciousness on admission should prompt immediate and aggressive management. 3. Timely neurosurgical consultation is essential when poor prognostic factors are identified. Contemporary studies and guidelines emphasize that early recognition and intervention are key in managing brain abscesses, especially when poor prognostic factors are present. Advances in neuroimaging and minimally invasive surgical techniques continue to improve outcomes, but the presence of multiple lesions, deep location, and altered consciousness remain consistent indicators of a poor prognosis.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "HSV encephalitis, duration of Acyclovir:",
    "option_a": "21 days",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "HSV encephalitis is a life\u2010threatening infection of the central nervous system caused by herpes simplex virus type 1. It primarily affects the temporal lobes and is treated with antiviral therapy to limit viral replication and reduce neurologic damage. HSV gains entry into the brain via retrograde transmission from peripheral nerves. It produces a hemorrhagic necrotizing encephalitis with significant inflammation, particularly within the temporal lobe. The use of acyclovir inhibits viral DNA polymerase, thereby reducing viral replication and damage. Current evidence supports a prolonged course to ensure viral clearance, especially in cases where the infection is severe or the immune response is compromised. Patients typically present with fever, altered mental status, seizures, and focal neurologic deficits. Early initiation of acyclovir is essential to reduce morbidity and mortality. A sufficient duration of therapy, generally 21 days, is needed to minimize the risk of relapse and neurological sequelae. Diagnosis relies on a combination of clinical suspicion, MRI findings (often showing hyperintensity in the medial temporal lobes), and CSF analysis with polymerase chain reaction (PCR) testing for HSV DNA. Differential diagnoses include other viral encephalitides (e.g., varicella zoster encephalitis), autoimmune encephalitis, and acute disseminated encephalomyelitis. First\u2010line management is intravenous acyclovir at a dose of 10 mg/kg every 8 hours for 21 days. Dose adjustments are necessary for patients with renal impairment. In pregnancy and lactation, acyclovir is categorized as relatively safe when used at therapeutic doses; however, careful monitoring and consultation with obstetric guidelines are advised. Option A (21 days) is correct because current guidelines recommend a 21\u2010day course of acyclovir to ensure complete viral suppression. Other options were not provided, but 21 days is the standard duration for CNS infections with HSV. \u2022 Early diagnosis and initiation of acyclovir are crucial for a favorable outcome. \u2022 A 21\u2010day regimen is recommended to prevent relapse. \u2022 Always adjust dosing in patients with renal impairment. Recent guidelines and studies continue to confirm that a 21\u2010day course of IV acyclovir is optimal in reducing morbidity and mortality in HSV encephalitis while minimizing the risk of relapse.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following infection that can cause internuclear ophthalmoplegia (INO)?",
    "option_a": "TB",
    "option_b": "HIV",
    "option_c": "cysticercosis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Internuclear ophthalmoplegia (INO) is a disorder of conjugate horizontal gaze caused by a lesion in the medial longitudinal fasciculus (MLF), which interconnects the abducens and oculomotor nuclei in the brainstem. Infections such as tuberculous meningitis can lead to a basal exudative inflammatory process that affects the brainstem. When the inflammatory exudates or tuberculomas involve the MLF, the result can be an INO. Although the classic causes of INO are demyelinating disorders (most notably multiple sclerosis) and vascular infarcts, infections causing brainstem inflammation (like TB) are recognized in endemic regions. Patients with TB meningitis may develop cranial nerve abnormalities including INO, which manifests as impaired adduction on the affected side with nystagmus in the abducting eye. The presence of systemic signs of infection along with meningitic symptoms further supports an infectious etiology. The differential diagnosis for INO primarily includes multiple sclerosis and ischemic stroke. In the setting of systemic symptoms or risk factors for tuberculosis, TB meningitis should be high on the list. Brain MRI combined with CSF analysis (including tests for Mycobacterium tuberculosis) can help to differentiate between these causes. Management of TB meningitis involves antituberculous therapy (typically a four-drug regimen like isoniazid, rifampicin, pyrazinamide, and ethambutol) often combined with corticosteroids to reduce inflammation. In pregnant or lactating women, most first\u2010line TB medications are considered safe but require monitoring for side effects and potential drug interactions. Option A (TB) is correct as tuberculous meningitis can cause a brainstem inflammatory process involving the MLF, leading to INO. Option B (HIV) is less directly associated with INO though HIV-associated demyelination may rarely mimic such findings. Option C (cysticercosis) can cause brainstem lesions but is not as commonly associated with an isolated INO presentation compared to TB in endemic settings. \u2022 INO is most often due to demyelination or vascular causes, but infections like TB should be considered in endemic areas. \u2022 TB meningitis can produce a wide variety of brainstem deficits including INO. Case reports and reviews in neurology literature have documented TB meningitis presenting with INO. The recognition of TB as an etiologic factor in brainstem syndromes continues to be highlighted in updated infectious disease and neurology guidelines.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with features of Whipple with Oculomasticatory myorhythmia what to do next",
    "option_a": "Jejunum biopsy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Whipple disease is a rare, systemic infectious disorder caused by the bacterium Tropheryma whipplei. It classically presents with a combination of gastrointestinal symptoms, arthralgias, weight loss, and, in some cases, neurologic manifestations, among which oculomasticatory myorhythmia is considered pathognomonic. The organism leads to infiltration of the intestinal lamina propria by PAS-positive macrophages, causing malabsorption. Its systemic spread can involve the central nervous system, which is when neurologic signs such as oculomasticatory myorhythmia (rhythmic contractions of the orbicularis oculi accompanied by masticatory muscle movements) occur. The presence of oculomasticatory myorhythmia in a patient with systemic symptoms (abdominal pain, diarrhea, and weight loss) strongly suggests Whipple disease. This makes it essential to confirm the diagnosis with a tissue biopsy. A small intestinal biopsy (commonly from the duodenum or jejunum) demonstrating PAS-positive, foamy macrophages is the gold standard diagnostic test. Differential diagnoses include other causes of malabsorption (e.g., celiac disease, inflammatory bowel disease) and infectious or neoplastic conditions affecting the gastrointestinal tract. After diagnosis, treatment involves an initial phase of intravenous antibiotics (typically ceftriaxone or penicillin with streptomycin) followed by long-term oral antibiotic therapy (commonly trimethoprim-sulfamethoxazole for 1 year). In pregnancy and lactation, TMP-SMX poses risks (eg, kernicterus in neonates, contraindicated in the first trimester and near term), so alternative regimens (like extended use of cephalosporins) may be considered. Option A (Jejunum biopsy) is correct because obtaining a biopsy of the small bowel (duodenal or jejunal) is the definitive next step in confirming Whipple disease via histopathologic evidence of PAS-positive macrophages. Other options were not provided. \u2022 Oculomasticatory myorhythmia is virtually pathognomonic for Whipple disease. \u2022 A small intestinal biopsy is essential for confirmation of the diagnosis. Advances in polymerase chain reaction (PCR) and immunohistochemical staining have enhanced the accuracy and speed of Whipple disease diagnosis, supporting early intervention.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Same scenario what is the treatment.",
    "option_a": "Fluconazole",
    "option_b": "Amphotericin.",
    "option_c": "",
    "option_d": ", not provided, is irrelevant. Therefore, the correct treatment is best represented by Option C.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "The treatment for Whipple disease requires a targeted antibiotic regimen rather than antifungal therapy. The goal is to eradicate Tropheryma whipplei from all affected tissues, including the gastrointestinal system and the central nervous system. Tropheryma whipplei is an intracellular bacterium that causes systemic inflammation by accumulating in macrophages. Effective therapy must penetrate intracellularly to clear the infection. Antifungal agents such as fluconazole and amphotericin are ineffective against this bacterium. Following diagnosis (typically confirmed by a small bowel biopsy), patients often exhibit multisystem involvement including neurologic and gastrointestinal symptoms that require prompt and effective antibiotic treatment to prevent relapse and progression. The diagnosis, once established via biopsy (and possibly confirmed by PCR), directs the treatment. Differential considerations such as fungal infections or other atypical bacterial causes are ruled out by histologic and molecular analyses. Current guidelines recommend an initial induction phase with intravenous ceftriaxone (or another appropriate beta-lactam antibiotic) for about 2 weeks followed by long-term oral trimethoprim-sulfamethoxazole (TMP-SMX) for up to 1 year. This tiered approach ensures initial rapid bacterial clearance followed by sustained suppression to prevent relapse. In pregnancy and lactation, TMP-SMX poses risks (especially during the first trimester and near term); in such cases, alternative regimens (e.g., prolonged cephalosporin therapy) should be considered with multidisciplinary consultation. Option A (Fluconazole) is incorrect because it is an antifungal agent with no activity against Tropheryma whipplei. Option B (Amphotericin) is also an antifungal and similarly inappropriate. The marked Option C, which although not explicitly detailed in the list, is intended to represent the proper antibiotic regimen (i.e., IV ceftriaxone followed by long-term TMP-SMX). Option D, not provided, is irrelevant. Therefore, the correct treatment is best represented by Option C. \u2022 Whipple disease requires prolonged and sequential antibiotic therapy to ensure complete eradication. \u2022 Antifungal agents have no role in the management of Whipple disease. \u2022 In women who are pregnant or lactating, antibiotic selection requires careful consideration due to potential fetal and neonatal risks. Recent literature emphasizes the importance of early combined antibiotic therapy to minimize relapse rates. Studies continue to support the use of an initial IV regimen (usually ceftriaxone) followed by a year-long course of oral TMP-SMX, with modifications as needed for special populations such as pregnant or lactating patients.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with feature of mucormycosis (black nasal mass with maxillary pain and bilateral cavernous sinus features) what is the mechanism of infection.",
    "option_a": "Direct invasion.",
    "option_b": "Transmit through Dural sinus.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Mucormycosis is an aggressive, opportunistic fungal infection typically seen in immunocompromised hosts, especially patients with uncontrolled diabetes or diabetic ketoacidosis. Infection usually begins when spores are inhaled and directly invade the nasal mucosa and paranasal sinuses. The fungi of the Mucorales order exhibit angioinvasion, rapidly invading blood vessel walls, causing thrombosis, tissue infarction, and necrosis. The characteristic black necrotic tissue seen in the nasal cavity results from vascular invasion and subsequent tissue ischemia. The mechanism is direct invasion of local tissues rather than hematogenous spread through dural sinuses. Patients typically present with facial pain, black necrotic eschars within the nasal cavity, sinusitis and may progress to involve the orbit and brain (including cavernous sinus involvement). The local direct tissue invasion explains the constellation of symptoms seen in rhinocerebral mucormycosis. Diagnosis is based on clinical examination, radiologic imaging (CT/MRI showing sinus involvement, bony destruction, or extension into the orbit/cranial structures) and definitive diagnosis via histopathological biopsy demonstrating broad, nonseptate hyphae with right-angled branching. Differential diagnoses include invasive aspergillosis and bacterial sinusitis, but the clinical context (especially in diabetic or immunocompromised patients) is key. The current management approach is aggressive, requiring prompt initiation of antifungal therapy (typically high-dose liposomal amphotericin B is first-line) and urgent surgical debridement. In pregnant or lactating patients, liposomal amphotericin B is preferred due to its relatively safe profile. Adjunctive therapies may include control of underlying risk factors such as hyperglycemia. Option A (Direct invasion) is correct because mucormycosis primarily infects tissues via inhaled spores that directly invade adjacent structures. Option B (Transmit through Dural sinus) is incorrect because the infection is not transmitted hematogenously through dural sinuses but invades directly from the sinuses to surrounding tissues. 1. Mucormycosis is frequently seen in patients with uncontrolled diabetes, especially those in ketoacidosis. 2. The characteristic black necrotic eschar is due to angioinvasion and subsequent tissue necrosis. 3. Early recognition and a multidisciplinary approach to treatment (medical and surgical) are crucial for improving outcomes. Latest guidelines emphasize early imaging, prompt surgical debridement, and liposomal amphotericin B as first-line therapy. Recent studies continue to support the concept that rapid direct tissue invasion, rather than hematogenous spread, is the primary pathogenic mechanism.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Indian with initial diagnosis tension-type headache Image of Brain CT without contrast showed multiple small calcifications?",
    "option_a": "Neurocysticercosis",
    "option_b": "Toxoplasmosis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Neurocysticercosis is the most common parasitic infection of the central nervous system globally, especially in regions where Taenia solium (pork tapeworm) infection is endemic. It is often incidentally found in patients undergoing neuroimaging, even when presenting with nonspecific symptoms like headache. The disease results from ingestion of T. solium eggs which then hatch and form larvae that invade the brain tissue. Over time, the cysticerci die and may calcify, leading to the appearance of small calcified lesions on CT scans. These calcifications are a residue of prior infection. Patients can present asymptomatically or with seizures, headaches, or other neurological deficits depending on cyst location and number. Although tension-type headache is a common primary headache, in endemic regions, incidental findings of calcifications on CT should prompt consideration of neurocysticercosis, especially when characteristic lesions are present. Diagnosis is established through neuroimaging (CT/MRI) detecting cystic lesions, colloidal vesicular stages, or calcifications. Differential diagnoses include tuberculomas, other parasitic infections, and vascular calcifications. Serologic tests (such as enzyme-linked immunoelectrotransfer blot) can help confirm the diagnosis. Management depends on the stage of the lesions. Active lesions may be treated with antiparasitic agents (albendazole being first-line) along with corticosteroids to reduce inflammatory responses. In patients with calcified lesions, typically no specific antiparasitic treatment is required as the lesions represent healed infection; management is often symptomatic. In pregnant or lactating patients, the use of antiparasitic therapy should be carefully considered against potential risks and benefits. Option A (Neurocysticercosis) is correct as the presence of multiple small calcifications on CT in an endemic region strongly supports a diagnosis of healed neurocysticercosis. Option B (Toxoplasmosis) is less likely because toxoplasmosis typically presents with ring-enhancing lesions in immunocompromised patients rather than small calcifications in an otherwise healthy adult. 1. Neurocysticercosis is the most common parasitic infection of the CNS in endemic areas. 2. Calcified lesions on CT usually represent the end stage of neurocysticercosis and are a marker of prior infection. 3. Management is tailored to the stage of the cysts and the patient\u2019s clinical presentation. Recent research highlights the importance of differentiating active vs. calcified lesions in neurocysticercosis and supports a tailored approach with antiparasitic therapy only for active disease. Consensus guidelines recommend the use of corticosteroids to manage perilesional edema when antiparasitic treatment is initiated.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_26.png"
  },
  {
    "question": "Patient came with progressive dementia over the last 6 months with startle and sensory myoclonus with DWI image showing cortical ribbon sign what is the diagnosis:",
    "option_a": "Prion disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Prion diseases, such as Creutzfeldt-Jakob disease (CJD), are rapidly progressive neurodegenerative disorders characterized by a rapidly deteriorating cognition, myoclonus, and distinct radiologic findings. The cortical ribbon sign on diffusion-weighted imaging (DWI) is a hallmark feature. Prion diseases result from the misfolding of the normal prion protein into a pathogenic isoform (PrPSc) that accumulates in neural tissue. This leads to spongiform changes, neuronal loss, and reactive gliosis. The abnormal deposition is responsible for the characteristic high signal intensity seen in the cerebral cortex on DWI, known as the cortical ribbon sign. The clinical presentation with rapidly progressive dementia, startle-induced myoclonus, and sensory myoclonus strongly points toward a prion disease. The evolution over months rather than years, combined with specific DWI findings, helps differentiate CJD from other neurodegenerative dementias. Diagnosis is based on clinical evaluation, MRI (particularly DWI and FLAIR sequences showing cortical ribboning and basal ganglia involvement), EEG (which may show periodic sharp wave complexes), and cerebrospinal fluid analysis including 14-3-3 protein studies. Differential diagnoses include Alzheimer\u2019s disease, vascular dementia, and other rapidly progressive dementias, but the acute course and imaging findings favor prion disease. There is currently no cure for prion diseases; treatment is primarily supportive and focused on symptom management. Patients should receive multidisciplinary supportive care, including management of myoclonus and other complications. In the context of pregnancy or lactation, supportive measures remain the mainstay, and any pharmacological intervention should be cautiously considered due to the lack of effective disease-modifying treatments. Option A (Prion disease) is correct because the combination of rapid cognitive decline, startle and sensory myoclonus, and the cortical ribbon sign on DWI is highly characteristic of Creutzfeldt-Jakob disease. Other options would not account for the rapid progression and specific imaging findings seen in prion diseases. 1. A rapid progression (weeks to months) of dementia with associated myoclonus is a red flag for prion disease. 2. The cortical ribbon sign on DWI is a key radiologic feature of CJD. 3. There is no curative treatment, so early diagnosis helps in planning supportive care and counseling families. The most recent research continues to support the use of DWI MRI as a sensitive diagnostic tool for prion diseases. Ongoing studies are investigating potential biomarkers and therapeutic targets, but current management remains supportive with no proven disease-modifying therapies.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Neurobrucellosis what to give (no rifampin or Bactrim in the choices)",
    "option_a": "Doxycycline",
    "option_b": "Ceftriaxone",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "Neurobrucellosis is the involvement of the central nervous system by Brucella species, a zoonotic organism. In treating neurobrucellosis, it\u2019s crucial to choose antibiotics that not only have activity against Brucella but also have adequate penetration into the cerebrospinal fluid (CSF). Brucella organisms, after entering the bloodstream from infected animals or their products, can cross the blood\u2013brain barrier and induce an inflammatory reaction in the meninges or brain parenchyma. This leads to a variety of clinical pictures such as meningitis, meningoencephalitis, or even focal neurological deficits. The inflammatory response is partly mediated by cytokines and granulomatous inflammation, contributing to tissue damage. Patients typically present with fever, headache, confusion, neck stiffness, and sometimes focal neurological deficits. The diagnosis is supported by a history of exposure (e.g., unpasteurized dairy consumption or occupational exposure) and confirmed by serological tests and CSF analysis showing lymphocytic predominance. The diagnosis is made through a combination of clinical features, laboratory tests (serology, blood cultures), and CSF analysis. Differential diagnoses include tuberculous meningitis, viral encephalitis, and fungal meningitis. Distinguishing features in brucellosis are a positive serology for Brucella and a history of exposure to risk factors. Based on current guidelines, treatment requires combination therapy for an extended duration (usually at least 6\u201312 weeks). First-line regimens traditionally include doxycycline and rifampin. However, due to the need for effective CSF penetration, ceftriaxone is added (often 2 g IV daily) in cases of neurobrucellosis. In scenarios where rifampin or TMP-SMX are not options, the use of ceftriaxone in combination with doxycycline becomes critical. In pregnancy and lactation, doxycycline is generally contraindicated (tetracyclines may affect fetal bone and teeth development), so ceftriaxone (which is generally safe) becomes even more important with alternative combinations considered per individual risk/benefit analysis. Option A (Doxycycline) is effective for systemic brucellosis but has suboptimal CSF penetration when used as a monotherapy. Option B (Ceftriaxone) offers excellent blood\u2013brain barrier penetration and is recommended as part of combination therapy for neurobrucellosis. Given the restrictions (no rifampin or TMP-SMX available), ceftriaxone is the best available option. 1. Neurobrucellosis requires combination antibiotic therapy with agents that achieve high CSF concentrations. 2. Always consider the patient\u2019s exposure history and the need for prolonged therapy to prevent relapse. 3. In pregnant patients, avoid doxycycline while ensuring effective CNS coverage. Recent studies support the use of a triple regimen (including ceftriaxone) for neurobrucellosis to reduce relapse rates. Ongoing research emphasizes the importance of tailored therapy based on CNS penetration, and clinical guidelines continue to recommend ceftriaxone as part of the regimen when first-line options cannot be used alone.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with meningitis came from Alhai found to have meningococcal meningitis what to give prophylaxis to the close contact (no rifampin in choices)",
    "option_a": "Ciprofloxacin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Meningococcal meningitis, caused by Neisseria meningitidis, is a highly infectious bacterial condition that requires prompt treatment and prophylaxis for close contacts to prevent secondary cases. N. meningitidis colonizes the nasopharynx and can invade the bloodstream and cross the blood\u2013brain barrier, triggering an intense inflammatory response in the meninges. The rapid progression of the disease is associated with endotoxin release, leading to septic shock and disseminated intravascular coagulation in severe cases. Clinically, patients present with high fever, headache, neck stiffness, altered mental status, and sometimes a petechial rash. The rapid progression and severity make early recognition and chemoprophylaxis for close contacts critical. Diagnosis is confirmed via CSF analysis (gram stain, culture, or PCR) and blood cultures. Differential diagnoses include other bacterial meningitides (like Streptococcus pneumoniae), viral meningitis, and encephalitis. Meningococcal meningitis is distinguished by its rapid course and characteristic rash in many cases. Guidelines recommend chemoprophylaxis for close contacts within 24 hours of diagnosis. Although rifampin is the conventional first-line prophylaxis, ciprofloxacin is an accepted alternative for adults when rifampin is contraindicated or not available. For pregnant contacts, however, alternatives such as ceftriaxone should be considered owing to the teratogenic potential of fluoroquinolones. Option A (Ciprofloxacin) is an effective alternative in adult prophylaxis when rifampin is not an option. Its single-dose regimen and efficacy make it a common choice, although care is needed in pregnant or pediatric populations. The absent alternate options in this question reaffirm that ciprofloxacin is the correct prophylactic choice for adult contacts in this context. 1. Early prophylaxis (within 24 hours) of close contacts is critical in controlling meningococcal outbreaks. 2. Always adjust prophylactic agents based on the patient\u2019s age, pregnancy status, and contraindications to specific medications. 3. Meningococcal disease can progress rapidly; high suspicion is necessary in endemic areas. CDC and WHO guidelines continue to endorse the use of ciprofloxacin as an alternative prophylactic agent in adult contacts of meningococcal disease, with ongoing studies comparing the efficacy and safety profiles of various regimens. Updated recommendations stress individual risk assessment, especially concerning pregnancy and pediatric considerations.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with CSF pic of lymphocytosis and eosinophilia showing schistosomiasis what is the treatment",
    "option_a": "Praziquantel",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Neuroschistosomiasis is a neurological manifestation resulting from infection with Schistosoma species. The treatment focuses on eliminating the parasite and reducing the inflammatory response caused by egg deposition in neural tissues. Schistosoma parasites have a complex life cycle involving freshwater snails and human hosts. When eggs lodge in the central nervous system, they provoke a granulomatous inflammatory response, resulting in CSF findings such as lymphocytosis and eosinophilia. The eosinophilic response is a hallmark of parasitic infections. Patients may present with a subacute onset of neurological deficits depending on the location of the lesion (spinal cord or brain). Symptoms can include weakness, sensory disturbances, and signs of increased intracranial pressure in cerebral involvement. Diagnosis is established by a combination of CSF analysis (revealing lymphocytic pleocytosis and eosinophilia), serologic tests, and imaging studies (MRI) that might show granulomatous lesions. Differential diagnoses include other causes of eosinophilic meningitis such as parasitic (e.g., Angiostrongylus cantonensis), fungal, or neoplastic processes. The first-line treatment for schistosomiasis is Praziquantel, which is effective against all major Schistosoma species. In neuroschistosomiasis, it is common to use Praziquantel combined with corticosteroids to mitigate the inflammatory response. For pregnant or lactating patients, Praziquantel is considered safe by the WHO in all trimesters, but clinical judgment should be exercised and counseling provided. Option A (Praziquantel) is the correct treatment. This drug directly targets the parasite\u2019s cell membrane, leading to paralysis and death of the parasite. Alternatives are limited and not as effective in this context, and many studies support its use as standard therapy. 1. The presence of eosinophils in CSF should always raise suspicion for parasitic infections. 2. Combination therapy with corticosteroids is often required to reduce neurological inflammation. 3. Early recognition and treatment of neuroschistosomiasis can prevent permanent neurological deficits. Recent guidelines and studies confirm that Praziquantel remains the cornerstone of schistosomiasis management. There is growing evidence for the adjunctive role of corticosteroids in reducing morbidity associated with inflammatory responses in neuroschistosomiasis.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Nurse got needle stick in her finger after blood extraction from a patient, she refuses to report it to infections control because the patient looks fine:",
    "option_a": "Report the incident.",
    "option_b": "Respect the nurse need.",
    "option_c": "Check the patient file",
    "option_d": "Screen the patient for HIV, HBV and HCV",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Needlestick injuries (NSIs) in healthcare settings represent a significant occupational hazard with the potential for transmission of bloodborne pathogens such as HIV, hepatitis B (HBV), and hepatitis C (HCV). Prompt action following an NSI is critical to ensure appropriate evaluation and management. A needle stick can inoculate pathogens directly into the tissue. The risk of transmission is contingent on the type of pathogen, the amount of blood involved, and the status of both the source and the exposed individual. Immediate reporting and evaluation help minimize the interval between exposure and the initiation of post-exposure prophylaxis (PEP). In practice, healthcare workers who suffer NSIs may develop anxiety about seroconversion. Prompt reporting ensures that baseline and follow-up testing can be performed and that appropriate PEP, if needed, is started without delay. After an NSI, the exposed worker should be risk stratified based on the type of injury and the source patient\u2019s serological status. Baseline testing for HIV, HBV, and HCV is recommended, followed by repeat testing at defined intervals. The differential considerations include assessing the need for prophylaxis versus watchful waiting, depending on the serostatus and exposure details. Management involves immediate reporting to the institutional occupational health or infection control department. This reporting triggers risk assessment, baseline serologic testing, and initiation of PEP if indicated. For example, if the source is HIV-positive, combination antiretroviral therapy is started as soon as possible (ideally within 1\u20132 hours). Vaccination status for hepatitis B should also be reviewed. For pregnant or lactating healthcare workers, the same protocols apply, with careful consideration of antiretroviral drug safety in pregnancy as guided by current CDC and NIH recommendations. Option A (Report the incident) is correct. This is the fundamental first step in NSI management. Option B (Respect the nurse\u2019s need) would neglect the potential risk to the nurse and delay necessary interventions. Option C (Check the patient file) is ancillary and insufficient on its own. Option D (Screen the patient for HIV, HBV, and HCV) is important as a subsequent step but must only be performed after proper reporting and risk assessment. 1. Time is of the essence in managing NSIs; early reporting can significantly reduce the risk of seroconversion. 2. Always follow hospital protocols for NSI management, regardless of the source patient\u2019s appearance. 3. Post-exposure prophylaxis is most effective when started promptly after exposure. Current CDC guidelines emphasize immediate reporting and prompt initiation of post-exposure prophylaxis. Recent research reinforces that delays in the management of NSIs significantly increase the risk of seroconversion and subsequent clinical disease, underscoring the importance of a systematic approach to NSI management.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "A male came from Africa to Saudi Arabia, has fever and other vague neurological symptoms and encephalopathy (cerebral malaria)",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "Neurological complications of parasitic infections represent a critical intersection between infectious disease and neurology, where systemic infections lead to central nervous system (CNS) dysfunction. Cerebral malaria, caused primarily by Plasmodium falciparum, is a prototypical example where parasitic infection induces profound neurological impairment. At its core, cerebral malaria involves disruption of normal cerebral function due to microvascular sequestration of parasitized erythrocytes, leading to encephalopathy. Understanding cerebral malaria requires integrating knowledge of neuroanatomy\u2014particularly cerebral microvasculature and the blood-brain barrier (BBB)\u2014with neurophysiology, including cerebral blood flow regulation and neuronal metabolism. The brain\u2019s vulnerability to hypoxia and inflammation underpins the clinical manifestations. As complexity increases, one must appreciate the roles of endothelial activation, cytokine release, and microvascular obstruction in producing the neurological syndrome, moving beyond simple infection to a multifactorial pathophysiological cascade. Cerebral malaria is almost exclusively caused by Plasmodium falciparum, which sequesters in the cerebral microvasculature and leads to encephalopathy. Clinically, cerebral malaria typically presents with fever, headache, and rapidly progressive encephalopathy characterized by altered consciousness, seizures, and sometimes focal neurological deficits. In endemic areas, children are most affected, but adults can also develop cerebral manifestations, especially in non-immune travelers or migrants. The encephalopathy reflects diffuse cerebral dysfunction from microvascular obstruction and inflammation. Other systemic signs include anemia, jaundice, and renal impairment due to multisystem involvement. The natural history without treatment is rapid progression to coma and death. Diagnosis is supported by history of travel to endemic regions, febrile illness, and detection of P. falciparum on peripheral blood smear. Neuroimaging may be normal or show cerebral edema but is not diagnostic. Key diagnostic findings include the presence of parasitemia combined with neurological symptoms in the absence of other causes. Early recognition is critical for prompt treatment to improve outcomes. Evaluation begins with a detailed travel and exposure history, focusing on endemic regions and symptom chronology. Laboratory diagnosis requires identification of P. falciparum parasites on peripheral blood smear using thick and thin films, which remains the gold standard due to high sensitivity and specificity. Rapid diagnostic tests (RDTs) detecting parasite antigens can be adjunctive but have variable sensitivity. Lumbar puncture is typically deferred initially due to risk of cerebral edema but may be necessary to exclude other causes of encephalopathy. Neuroimaging (MRI or CT) is generally non-specific but useful to rule out alternative diagnoses or complications such as hemorrhage. Electroencephalography (EEG) may show diffuse slowing consistent with encephalopathy. WHO criteria for cerebral malaria diagnosis emphasize coma (Glasgow Coma Scale <11 or Blantyre Coma Scale \u22642 in children) with confirmed parasitemia and exclusion of other causes. Early diagnosis is essential to initiate life-saving therapy. According to the WHO Guidelines for the Treatment of Malaria (3rd edition, 2015), the cornerstone of cerebral malaria treatment is prompt administration of intravenous artesunate, which has demonstrated superiority over quinine in reducing mortality (Dondorp et al., NEJM 2010). First-line therapy is intravenous artesunate for at least 24 hours followed by a full course of oral artemisinin-based combination therapy (ACT). Supportive care includes management of complications such as seizures, hypoglycemia, anemia, and cerebral edema. Adjunctive therapies like corticosteroids or mannitol have not shown benefit and are not recommended. Second-line options like intravenous quinine are reserved for settings where artesunate is unavailable. Mechanistically, artesunate rapidly kills intraerythrocytic parasites, reducing sequestration and inflammation. Long-term care involves monitoring for neurological sequelae and rehabilitation. Early treatment initiation is critical to improve survival and neurological outcomes. Since the question states the correct answer is 'None' and focuses on cerebral malaria, we analyze why other options (not provided here) would be incorrect in this clinical context. For example, if options included bacterial meningitis, viral encephalitis, or other parasitic infections like toxoplasmosis, these would be incorrect because: - Bacterial meningitis typically presents with meningeal signs and CSF pleocytosis, absent in cerebral malaria. - Viral encephalitis often has a subacute course with CSF lymphocytic pleocytosis and characteristic imaging findings. - Other parasitic infections have different geographic distributions, clinical features, and diagnostic tests. The key discriminating feature is the presence of P. falciparum parasitemia with encephalopathy in a traveler from an endemic area, consistent with cerebral malaria. The 'None' correct answer likely indicates no alternative diagnosis fits better than cerebral malaria in this scenario. - Always consider travel history in patients presenting with fever and neurological symptoms. - Cerebral malaria should be suspected in any patient from endemic areas with altered consciousness and fever. - Peripheral blood smear remains the diagnostic gold standard; do not rely solely on RDTs. - Early intravenous artesunate reduces mortality significantly compared to quinine. - Avoid lumbar puncture until cerebral edema is excluded. - Neurological sequelae can persist despite treatment; early supportive care is essential. - Distinguish cerebral malaria from other causes of encephalopathy by combining clinical, laboratory, and epidemiological data. Memory aid: 'FEVER' - Fever, Encephalopathy, Visit to endemic area, Evidence of parasitemia, Rapid treatment needed. The 2015 WHO Guidelines for the Treatment of Malaria state: \u201cIntravenous artesunate is the treatment of choice for severe malaria, including cerebral malaria, due to its superior efficacy and safety profile compared to quinine.\u201d (WHO, 2015). The landmark SEAQUAMAT trial (Dondorp et al., NEJM 2010) demonstrated a 22.5% reduction in mortality with artesunate. Despite advances, gaps remain in understanding adjunctive therapies to reduce cerebral edema and inflammation. Recent studies explore biomarkers for prognosis but none are yet validated for routine use. The role of neuroimaging is evolving, with MRI showing promise in elucidating cerebral involvement. Controversies persist around management of raised intracranial pressure and the utility of steroids, which are currently not recommended. Ongoing research aims to optimize supportive care and reduce long-term neurological deficits.",
    "exam_year": "2020",
    "exam_type": "Part I"
  }
]